PLG and neoplasm: Systemic delivery of ECFC expressing fms-like tyrosine kinase-1 and/or angiostatin-endostatin fusion protein was able to inhibit tumor growth, reduced tumor volume and increased survival in mice cancer models (106, 107), indicating ECFC as potential candidates for tumor-specific delivery of cancer gene therapy.